Sleep Quality & Psoriatic Arthritis
For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.
Read more →What's hot
View all perspectives
What's Hot
Ultrasound in PsA
Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study
Watch video →
Tapering TNFi in nonradiographic AxSpA
Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.
Watch video →
Sunday (Day 2): ACR 22 Daily Recap
ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.
Watch video →
Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression
Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)
Watch video →
Deucravacitinib in PsA
Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial
Watch video →
Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial
Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Watch video →
PET CT Imaging to Define Risk of Progression from PSO to PsA
Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.
Watch video →
ACR22 Daily Recap: Saturday Recap
Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate.
Watch video →
Eric Dein ericdeinmd
3 years 1 month ago
Ab0673 #ACR22 Occurrence & Severity of ITP w or w/o APLS antibodies
Fewer bleeding events in ITP patients w/ aPL antibodies (15% vs 43%) compared to w/o aPL antibodies
Despite more use of a/c and lower median patients in aPL patients
Is aPL Ab a good prognosis for ITP?
@RheumNow https://t.co/yLBVUN2T0L
Dr. Rachel Tate uptoTate
3 years 1 month ago
Hear Dr. @AngusWorthing discuss advocacy and more legislative updates at #ACR22 @RheumNow https://t.co/zD8xpcCzi2
Dr. Antoni Chan synovialjoints
3 years 1 month ago
IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in
◦ total spinal pain (SP)
◦ nocturnal SP
◦ morning stiffness (BASDAI)
◦ fatigue (FACIT-F)
Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB
#ACR22 @RheumNow
Richard Conway RichardPAConway
3 years 1 month ago
Fava et al. Urinary biomarkers at 3 months better than UPCR in predicting 12 month treatment response in SLE nephritis . CD163 AUC 0.83 vs 0.75 for UPCR @THKC1 @RheumNow #ACR22 Abstr#0536 https://t.co/YI3JC2uKcv https://t.co/jnkfbI0Z1M
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Here is a quick recap on #ACR22 Abstr#0355 Effect of voclosporin in class V lupus nephritis #lupus https://t.co/0cR8On5UWN via @YouTube @RheumNow https://t.co/E25so6X2fj
Interstitial lung disease (ILD) remains a leading cause of mortality in rheumatoid arthritis (RA). Estimates of involvement of ILD in RA remain relatively imprecise (estimated prevalence 5-20%), though this partly reflects the wide spectrum of ILD and differing ascertainment.
Richard Conway RichardPAConway
3 years 1 month ago
Wilson et al. Sputum ACPA or RF assoc RA development in serum ACPA+ individuals. x4 more likely - 46% vs 12%. @RheumNow #ACR22 Abstr#0533 https://t.co/7kpeXWjeKI https://t.co/Sx41DOJAAX
Md Yuzaiful Md Yusof Yuz6Yusof
3 years 1 month ago
Please do catch up on my interview with Dr Amit Saxena, New York on their work. #ACR22 Abstr#2081 Breakthrough COVID infection in SLE during Omicron era https://t.co/4dINWSobxj via @YouTube @RheumNow https://t.co/hIHWGRcu5h
Richard Conway RichardPAConway
3 years 1 month ago
Riskedal et al. DNA methyllation based biomarker for sero- RA. Accurary 1.0 for sero+ RA and reactive arthritis, 0.75 sero-RA, 0.5 PsA. Promising but not there yet. @RheumNow #ACR22 Abstr#0531 https://t.co/clLR0V33WJ https://t.co/7Hts9gtkW9
Dr. Rachel Tate uptoTate
3 years 1 month ago
Preliminary results anifrolumab may be effective in highly recalcitrant & RTX resistant CLE and DLE. Abs 0974 #ACR22 @RheumNow https://t.co/FeYrdlwQsA
Richard Conway RichardPAConway
3 years 1 month ago
Gomez et al. Predictors renal flare in SLE. Adjusted models - low C3, low albumin, proteinuria. @RheumNow #ACR22 Abstr#0540 https://t.co/POfeAa9Ao9 https://t.co/a3JkSP1MkX
Eric Dein ericdeinmd
3 years 1 month ago
In-person meetings are tough. Virtual meetings are tough. But hybrid meetings are logistical nightmares
Would've liked better WiFi and a live poster hall, but a HUGE credit to @ACRheum on planning a great #ACR22 hybrid meeting. Really amazing job
@RheumNow
Dr. Antoni Chan synovialjoints
3 years 1 month ago
Getting to know the COVID-19 drugs:
◦ Pre-exposure prophylaxis: Tixagevimab and cilgavimab (Evusheld)
◦ Post-exposure treatments: Paxlovid (po), Molnupiravir (po), Sotrovimab (IV), Remdesivir (IV)
Rachael Perritt, COVID-19, #ACR22 @RheumNow https://t.co/bCwxJ9YfIU
Dr. John Cush RheumNow
3 years 1 month ago
Show us how you ACR! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/aAUyhmrLPW
Poster Hall